Science Media Centre

expert reaction to study of blood based diagnostic biomarkers for ME/CFS

Bioengineer.org

New Blood Biomarkers Uncovered for ME/CFS Diagnosis

Daily Mirror

Scientists claim to have developed first ever blood test to diagnose ME

Scientists Develop First Ever Blood Test To Diagnose Chronic Fatigue Syndrome

The National

Scientists develop first-ever blood test to diagnose ME

The Times

First blood test to diagnose chronic fatigue syndrome

Medicalxpress

Novel blood test for chronic fatigue achieves 96% accuracy

Independent

News Medical

Scientists develop a high accuracy blood test to diagnose Chronic Fatigue Syndrome

Guardian

Scientists develop first accurate blood test to detect chronic fatigue syndrome

BioMed Central

Development and validation of blood-based diagnostic biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using EpiSwitch 3-dimensional genomic regulatory immuno-genetic profili

Sky News

Scientists develop first-ever blood test to diagnose chronic fatigue syndrome

New Atlas

'Breakthrough' blood test detects chronic fatigue in 92% of cases

The Telegraph

Breakthrough Blood Test Can Detect Chronic Fatigue Syndrome

OxBioDynamics

Researchers from the University of East Anglia and Oxford Biodynamics have developed a blood test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), utilizing EpiSwitch 3D genomics technology to analyze DNA folding patterns in blood samples from 47 patients with severe ME/CFS and 61 healthy controls.

Researchers from the University of East Anglia and Oxford Biodynamics have developed a blood test for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), utilizing EpiSwitch 3D genomics technology to analyze DNA folding patterns in blood samples from 47 patients with severe ME/CFS and 61 healthy controls.

The test demonstrated 92% sensitivity in identifying ME/CFS cases and 98% specificity in ruling out negative cases, achieving an overall accuracy of 96%, according to findings published in the Journal of Translational Medicine on Tuesday.

The test demonstrated 92% sensitivity in identifying ME/CFS cases and 98% specificity in ruling out negative cases, achieving an overall accuracy of 96%, according to findings published in the Journal of Translational Medicine on Tuesday.

The test identifies epigenetic markers that change during a person's life, rather than the fixed genetic code, as chronic fatigue syndrome is not a genetic disease that people are born with, according to scientists at Oxford Biodynamics.

The test identifies epigenetic markers that change during a person's life, rather than the fixed genetic code, as chronic fatigue syndrome is not a genetic disease that people are born with, according to scientists at Oxford Biodynamics.

ME/CFS affects more than 400,000 people in the U.K. and is characterized by extreme fatigue not relieved by rest. Patients often go undiagnosed for years due to the absence of definitive diagnostic tests.

ME/CFS affects more than 400,000 people in the U.K. and is characterized by extreme fatigue not relieved by rest. Patients often go undiagnosed for years due to the absence of definitive diagnostic tests.

Professor Chris Ponting, chairman of medical bioinformatics at the University of Edinburgh, expressed caution about the findings, stating the test requires validation in better-designed independent studies and would likely cost around £1,000 if approved for clinical use.

Professor Chris Ponting, chairman of medical bioinformatics at the University of Edinburgh, expressed caution about the findings, stating the test requires validation in better-designed independent studies and would likely cost around £1,000 if approved for clinical use.

However, researchers hope the breakthrough could pave the way for similar diagnostic tests for long COVID, as post-COVID syndrome represents one example of ME/CFS, where the COVID-19 virus triggers symptoms.

However, researchers hope the breakthrough could pave the way for similar diagnostic tests for long COVID, as post-COVID syndrome represents one example of ME/CFS, where the COVID-19 virus triggers symptoms.

Science Media Centre #

Bioengineer.org #

Daily Mirror #

ITV #

The National #

The Times #

Medicalxpress #

Independent #

News Medical #

Guardian #

BioMed Central #

Sky News #

New Atlas #

The Telegraph #

Researchers from the University of East Anglia and Oxford Biodynamics developed a blood test for chronic fatigue syndrome using EpiSwitch 3D genomics technology that analyzes DNA folding patterns in blood samples from 47 severe ME/CFS patients and 61 healthy controls.</span

Researchers from the University of East Anglia and Oxford Biodynamics developed a blood test for chronic fatigue syndrome using EpiSwitch 3D genomics technology that analyzes DNA folding patterns in blood samples from 47 severe ME/CFS patients and 61 healthy controls.

The test demonstrated 92% sensitivity in identifying ME/CFS cases and 98% specificity in ruling out negative cases, achieving an overall accuracy of 96% according to findings published in the Journal of Translational Medicine.</span

The test demonstrated 92% sensitivity in identifying ME/CFS cases and 98% specificity in ruling out negative cases, achieving an overall accuracy of 96% according to findings published in the Journal of Translational Medicine.

ME/CFS affects more than 400,000 people in the UK and is characterized by extreme fatigue not relieved by rest, with patients often going undiagnosed for years due to the absence of definitive diagnostic tests.</span

ME/CFS affects more than 400,000 people in the UK and is characterized by extreme fatigue not relieved by rest, with patients often going undiagnosed for years due to the absence of definitive diagnostic tests.

The test identifies epigenetic markers that change during a person's life rather than fixed genetic code, as chronic fatigue syndrome is not a genetic disease people are born with, according to Oxford Biodynamics scientists.</span

The test identifies epigenetic markers that change during a person's life rather than fixed genetic code, as chronic fatigue syndrome is not a genetic disease people are born with, according to Oxford Biodynamics scientists.

Medical experts expressed caution about the findings, stating the test requires validation in better-designed independent studies and would likely cost around £1,000 if approved for clinical use.</span

Medical experts expressed caution about the findings, stating the test requires validation in better-designed independent studies and would likely cost around £1,000 if approved for clinical use.

Researchers hope the breakthrough could pave the way for similar diagnostic tests for long COVID, as post-COVID syndrome represents one example of ME/CFS where symptoms are triggered by the COVID-19 virus.</span

Researchers hope the breakthrough could pave the way for similar diagnostic tests for long COVID, as post-COVID syndrome represents one example of ME/CFS where symptoms are triggered by the COVID-19 virus.

This revolutionary blood test represents a monumental breakthrough for ME/CFS patients who have suffered for decades without proper diagnostic tools. The EpiSwitch technology delivers an unprecedented 96% accuracy rate, finally providing concrete biological evidence that validates this debilitating condition and offers hope to millions worldwide.

This revolutionary blood test represents a monumental breakthrough for ME/CFS patients who have suffered for decades without proper diagnostic tools. The EpiSwitch technology delivers an unprecedented 96% accuracy rate, finally providing concrete biological evidence that validates this debilitating condition and offers hope to millions worldwide.</span

This study's impressive claims fall apart under scrutiny — it only tested severe, housebound patients against perfectly healthy controls, ignoring those with similar conditions like depression or fibromyalgia. The 96% accuracy figure is misleading statistical hype that could drop to just 73% in real-world applications.

This study's impressive claims fall apart under scrutiny — it only tested severe, housebound patients against perfectly healthy controls, ignoring those with similar conditions like depression or fibromyalgia. The 96% accuracy figure is misleading statistical hype that could drop to just 73% in real-world applications.</span

New Blood Test Shows 96% Accuracy in Diagnosing ME/CFS

Diseases & conditions

Health

This revolutionary blood test is a monumental breakthrough for ME/CFS patients who have suffered for decades without proper diagnostic tools. The EpiSwitch technology delivers an unprecedented 96% accuracy rate, finally providing concrete biological evidence that validates this debilitating condition and offers hope to millions worldwide.

This revolutionary blood test is a monumental breakthrough for ME/CFS patients who have suffered for decades without proper diagnostic tools. The EpiSwitch technology delivers an unprecedented 96% accuracy rate, finally providing concrete biological evidence that validates this debilitating condition and offers hope to millions worldwide.

This study's impressive claims fall apart under scrutiny — it only tested severe, housebound patients against perfectly healthy controls, ignoring those with similar conditions like depression or fibromyalgia. The 96% accuracy figure is misleading statistical hype that could drop to just 73% in more difficult, real-world applications.

This study's impressive claims fall apart under scrutiny — it only tested severe, housebound patients against perfectly healthy controls, ignoring those with similar conditions like depression or fibromyalgia. The 96% accuracy figure is misleading statistical hype that could drop to just 73% in more difficult, real-world applications.

There's a 50% chance that there will be a breakthrough in the treatment of hard-to-treat cancers before February 2031, according to the Metaculus prediction community.

There's a 50% chance that there will be a breakthrough in the treatment of hard-to-treat cancers before February 2031, according to the Metaculus prediction community.

Scientists Develop First Blood Test to Detect Chronic Fatigue

NewScientists Develop First Blood Test Showsto 96%Detect AccuracyChronic in Diagnosing ME/CFSFatigue

The Spin

Metaculus Prediction

Articles on this story